Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Advanced Clear Cell Renal Cell Carcinoma
NCT06940518Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in clear cell renal cell carcinoma (ccRCC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate, Disease Control Rate at 24 weeks and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06940518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940518.